<DOC>
	<DOCNO>NCT03106324</DOCNO>
	<brief_summary>This post authorization safety study design prospective non interventional study patient newly diagnose multiple myeloma eligible transplant . The objective compare incidence cardiovascular event patient treat first-line lenalidomide contain regimen treat first-line non-lenalidomide contain regimen . Treatment cohorts do accord standard care . The study gather risk factor information baseline throughout follow-up . Any cardiovascular event occur assessed independent committee . Other safety endpoint collect standard procedure . Observation period 3 year treatment , additional evaluation cardiovascular event 6 month ' post treatment follow period 5 year inclusion . During follow incidence second primary malignancy ( SPM ) overall survival assess .</brief_summary>
	<brief_title>A Safety Study Lenalidomide Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible Transplant</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>1 . Must understand voluntarily sign Informed Consent Form ( ICF ) 2 . Age â‰¥ 18 year time sign ICF 3 . Newly diagnose multiple myeloma 4 . Must eligible transplant 5 . Will treat firstline lenalidomidecontaining nonlenalidomidecontaining regimen , currently treat firstline regimen receive less 2 cycle . 1 . Prior treatment Monoclonal gammopathy undetermined significance ( MGUS ) smolder myeloma lenalidomide , thalidomide , pomalidomide agent consider firstline Multiple myeloma ( MM ) therapy . 2 . Prior treatment lenalidomide , thalidomide , pomalidomide agent consider firstline MM therapy clinical trial participation patient access program 3 . Two complete cycle firstline therapy agent consider firstline MM therapy newly diagnose multiple myeloma ( NDMM ) treatment study enrollment 4 . Refusal participate Revlimid Transplant noneligible ( TNE ) Newly diagnose multiple myeloma ( NDMM ) Postauthorization safety study ( PASS ) current participation treatment phase interventional clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Non transplant eligible</keyword>
	<keyword>Revlimid</keyword>
	<keyword>PASS</keyword>
	<keyword>Non-interventional</keyword>
	<keyword>Lenalidomide</keyword>
</DOC>